For instance, the American Diabetes Association only recommends the use of GLP-1 drugs for weight loss for those with a body mass index, or BMI, of at least 30, or among those with a BMI of 27 or greater if they have at least one other condition such as type 2 diabetes, hypertension or high cholesterol
The debate surrounding GLP-1 medicines presents a remarkably similar challenge, but in a less visible context
Deze route lijkt makkelijk, maar komt wel met verschillende risicos: Het middel wordt gebruikt door mensen die het medisch gezien niet altijd nodig hebben
Neuronal activity regulates astrocytic Nrf2 signaling
Patients should always rotate injection sites to avoid irritation or tissue damage
There are many potential/partial explanations for this difference: Tirzepatide is a dual agonist (for GIP/GLP-1), making it an arguably more structurally complex molecule and less tenable for recombinant expression (though both are linear peptides with a side chain)
